The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|May 10, 2022
Rheumatoid Arthritis Quiz: RA and Cardiovascular Risk
Author(s)Ingrid Torjesen
Rheumatoid arthritis is known risk factor for cardiovascular disease, but how much do you know about the association? Test your knowledge with this quiz.
Advertisement
By how much is the risk of cardiovascular disease increased in patients with rheumatoid arthritis compared to the general population?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement